About this trial
A clinical trial of exercise-similar heart rate acceleration delivered via cardiac pacing vs. sham intervention in subjects at rest will be performed. The study population comprises subjects with guideline-directed medically managed left ventricular dysfunction due to ischemic or non-ischemic cardiomyopathy and an existing implantable cardioverter defibrillator or biventricular implantable cardioverter defibrillator. The purpose of the study is to understand how the heart rate pattern of exercise contributes to the considerable cardiac conditioning effects of exercise and estimate whether the pacing approach may have translational clinical applicability. Fifty-two subjects will be randomized, single-blinded, to either the pacing intervention or a sham intervention which they will receive once daily, 3 days/week for 6 weeks. Baseline symptoms and clinical test results will be compared to the same measures at 2 weeks, 4 weeks and 6 weeks of intervention/sham and at 3 months and one-year post-intervention. The primary endpoint will be the change in left ventricular ejection fraction from baseline in intervention vs. sham groups (mixed effects linear regression with time and treatment arm as fixed effects and pre-specified covariates of sex and cardiomyopathy type as random effects). Secondary endpoints will include changes in quality of life, 6-minute walk distance, cardiopulmonary exercise test (CPET) measures, daily activity and major adverse cardiac events (MACE) at 3 and 12 months between pacing and sham groups. A "dose-response" analysis of outcomes at 2, 4, and 6 weeks of the intervention vs. sham compared with baseline will be performed.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Provision of signed and dated informed consent form
Stated willingness to comply with all study procedures and availability for the duration of the study
Male or female sex
Age 18 years or greater
Disqualifiers
Age < 18 years
Inability to ambulate safely
Congenital or primary valve disease
Ongoing (not suppressed) atrial arrhythmias
Trial design
Parallel
Treatments tested in this trial
Exercise-similar cardiac pacing
DeviceCardiac pacing using subjects already-implanted cardioverter defibrillator to reproduced exercise heart rate envelope.
Sham cardiac pacing
DeviceSimulated (rates selected using programmer but not initiated) cardiac pacing using subjects already-implanted cardioverter defibrillator to reproduced exercise heart rate envelope.
Treatment groups
Trial outcomes
Primary outcomes
Change in left ventricular ejection fraction by echocardiogram
The change in left ventricular ejection fraction from baseline as determined by echocardiography
Secondary outcomes
Quality of Life score on the Minnesota Living with Heart Failure questionnaire
Numerical score based on a subject's subjective symptoms and functional status
Quality of Life score on the Kansas City Cardiomyopathy Questionnaire
Numerical score based on a subject's subjective symptoms and functional status
6-minute walk distance
Distance on a standard 6-minute walk measured in meters
Cardiopulmonary exercise test maximum oxygen consumption
V02max (maximum milliliters of oxygen consumed per kilogram of body weight per minute)
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Denice Hodgson-Zingman, MD
Lead sponsor
University of Iowa
Sponsor institution
The Cleveland Clinic
Collaborator
National Institutes of Health (NIH)
Collaborator
National Heart, Lung, and Blood Institute (NHLBI)
Collaborator